Mark T. Iwicki - 22 Jun 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Eric Trachtenberg, Attorney-in-Fact
Issuer symbol: KALA
Transactions as of: 22 Jun 2023
Transactions value $: $0
Form type: 4
Filing time: 23 Jun 2023, 20:00:07 UTC
Previous filing: 12 Jun 2023
Next filing: 27 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALA	Common Stock	Award	$0	+159K	+135%	$0.00	277K	22 Jun 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALA	Stock Option (right to buy)	Award	$0	+212K		$0.00	212K	22 Jun 2023	Common Stock	212K	$14.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
F2	Includes 272,795 unvested RSUs.
F3	This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.